“Rather than renting a therapeutic benefit on a month‑to‑month basis, we should be looking at it more as a long‑term investment – going from renting to owning.”Abi Pinchbeck, Commissioning Editor, Cell & Gene Therapy Insights, speaks with David Barrett, CEO, American Society of Gene & Cell Therapy, about the evolving role of the organization as the field it serves accelerates, the CGTxchange initiative to rehome deprioritized assets, and the urgent question of how reimbursement models must evolve to get these therapies to the patients who need them.
David M Barrett (Wed,) studied this question.